In GBM, fibrinogen-like Protein 2 (FGL2), produced by tumor cells, interfered with GM-CSF signaling, blunting the differentiation of CD103+ cDC1s and consequently, lowering the CD8+ T-cell response [155]. This evidence concerns the gene FGL2 and neoplasm.